Pulmonary arterial hypertension (PAH) affected an estimated 192,000 individuals globally in 2021, disproportionately affecting women and older adults.
People with pulmonary arterial hypertension (PAH) experience a high disease burden and their quality of life worsens as their ...
In patients with familial PAH, SMAD5 appears to be a novel gene that warrants consideration for genetic testing, according to ...
Regulators squeezed in two final approvals before the calendar change with the UK approval of Merck’s Winrevair and the FDA’s ...
The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.
Medpage Today on MSN5d
Have the New Pulmonary Hypertension Drugs Changed the Game?Both PULSAR and STELLAR "showed impressive results on hemodynamics and other clinical endpoints suggesting that this might be ...
The top articles about pulmonary arterial hypertension (PAH) in 2024 included FDA approvals, the effect of salt substitutes ...
Increasing average concentrations of sotatercept improved 6-minute walk distance, pulmonary vascular resistance, and levels of NT-proBNP.
“Investigating the association between metabolic traits and PAH provides new insights into the [disease’s] underlying ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback